Bellast Ultra L Dermal Filler
Next-generation cross-linked HA filler with 98.7% polymerization efficiency & 20mg/ml concentration
Advanced Cross-Linking Technology
Utilizing double polymerization technology (KR Patent 1020210034567), Bellast Ultra L achieves optimal viscosity (G’ 350Pa) with 20mg/ml non-animal hyaluronic acid. Manufactured under ISO 13485 standards with endotoxin levels <0.5 EU/ml (validated by LAL testing). Contains 0.3% lidocaine HCl for pain management during administration.
Clinical Advantages
Superior Viscosity
G’ value of 350Pa provides optimal tissue integration and natural-looking results
Safety Profile
BDDE residual <2ppm (HPLC tested) with 0.3% lidocaine for comfort
Longevity
9-12 month duration confirmed in 24-month cohort study (n=180)
Product Specifications
- Active Ingredients: HA 20mg/ml, Lidocaine 0.3%
- BDDE Residual: <2ppm
- Packaging: 1×1ml sterile syringe
- Viscosity: G’ 350Pa @2Hz
- Certification: ISO 13485:2016
Clinical Protocol
- Needle: 30G×4mm (27G for deep injection)
- Depth: Mid to deep dermis (1.5-2.5mm)
- Max Volume: 1ml per session
- Technique: Linear threading or serial puncture
Indications
Nasolabial Folds
Inject 0.2-0.4ml per fold using 30G needle. Maintain subdermal placement for optimal spread.
Lip Augmentation
Limit to 0.6ml per session. Use vertical injection technique in vermilion border.
Marionette Lines
Administer 0.3-0.5ml per side using fanning technique at dermal-subdermal junction.
Medical Notice
Important: Individual results may vary based on skin type, age, and injection technique. Must be administered by licensed medical professionals. Contraindicated in pregnancy, active skin infections, or history of severe allergic reactions.
Post-procedure monitoring required for 30 minutes. Notify manufacturer immediately of any adverse events. Store at 2-25°C. Do not freeze. Use within 24 hours of opening.
